Haris Zahoor1, James D Luketich2, Ryan M Levy2, Omar Awais2, Daniel G Winger3, Michael K Gibson4, Katie S Nason5. 1. Department of Medicine, University of Pittsburgh, Pittsburgh, Pa. 2. Department of Cardiothoracic Surgery, University of Pittsburgh, Pittsburgh, Pa. 3. Clinical and Translational Science Institute, University of Pittsburgh, Pittsburgh, Pa. 4. Department of Medicine, Case Western Reserve University, Cleveland, Ohio. 5. Department of Cardiothoracic Surgery, University of Pittsburgh, Pittsburgh, Pa. Electronic address: nasonks@upmc.edu.
Abstract
OBJECTIVES: Prognosis for patients with locally advanced esophagogastric adenocarcinoma (EAC) is poor with surgery alone, and adjuvant therapy after open esophagectomy is frequently not tolerated. After minimally invasive esophagectomy (MIE); however, earlier return to normal function may render patients better able to receive adjuvant therapy. We examined whether primary MIE followed by adjuvant chemotherapy influenced survival compared with propensity-matched patients treated with neoadjuvant therapy. METHODS: Patients with stage II or higher EAC treated with MIE (N = 375) were identified. Using 30 pretreatment covariates, propensity for assignment to either neoadjuvant followed by MIE (n = 183; 54%) or MIE as primary therapy (n = 156; 46%) was calculated, generating 97 closely matched pairs. Hazard ratios were adjusted for age, sex, body mass index, smoking, comorbidity, and final pathologic stage. RESULTS: In propensity-matched pairs, adjusted hazard ratio for death did not differ significantly for primary MIE compared with neoadjuvant (hazard ratio, 0.83; 95% confidence interval, 0.60-1.16). Recurrence patterns were similar between groups and 65% of patients with IIb or greater pathologic stage received adjuvant therapy. Clinical staging was inaccurate in 37 out of 105 patients (35%) who underwent primary MIE (n = 18 upstaged and n = 19 downstaged). CONCLUSIONS: Primary MIE followed by adjuvant chemotherapy guided by pathologic findings did not negatively influence survival and allowed for accurate staging compared with clinical staging. Our data suggest that primary MIE in patients with resectable EAC may be a reasonable approach, improving stage-based prognostication and potentially minimizing overtreatment in patients with early stage disease through accurate stage assignments. A randomized controlled trial testing this hypothesis is needed.
OBJECTIVES: Prognosis for patients with locally advanced esophagogastric adenocarcinoma (EAC) is poor with surgery alone, and adjuvant therapy after open esophagectomy is frequently not tolerated. After minimally invasive esophagectomy (MIE); however, earlier return to normal function may render patients better able to receive adjuvant therapy. We examined whether primary MIE followed by adjuvant chemotherapy influenced survival compared with propensity-matched patients treated with neoadjuvant therapy. METHODS:Patients with stage II or higher EAC treated with MIE (N = 375) were identified. Using 30 pretreatment covariates, propensity for assignment to either neoadjuvant followed by MIE (n = 183; 54%) or MIE as primary therapy (n = 156; 46%) was calculated, generating 97 closely matched pairs. Hazard ratios were adjusted for age, sex, body mass index, smoking, comorbidity, and final pathologic stage. RESULTS: In propensity-matched pairs, adjusted hazard ratio for death did not differ significantly for primary MIE compared with neoadjuvant (hazard ratio, 0.83; 95% confidence interval, 0.60-1.16). Recurrence patterns were similar between groups and 65% of patients with IIb or greater pathologic stage received adjuvant therapy. Clinical staging was inaccurate in 37 out of 105 patients (35%) who underwent primary MIE (n = 18 upstaged and n = 19 downstaged). CONCLUSIONS: Primary MIE followed by adjuvant chemotherapy guided by pathologic findings did not negatively influence survival and allowed for accurate staging compared with clinical staging. Our data suggest that primary MIE in patients with resectable EAC may be a reasonable approach, improving stage-based prognostication and potentially minimizing overtreatment in patients with early stage disease through accurate stage assignments. A randomized controlled trial testing this hypothesis is needed.
Authors: P van Hagen; M C C M Hulshof; J J B van Lanschot; E W Steyerberg; M I van Berge Henegouwen; B P L Wijnhoven; D J Richel; G A P Nieuwenhuijzen; G A P Hospers; J J Bonenkamp; M A Cuesta; R J B Blaisse; O R C Busch; F J W ten Kate; G-J Creemers; C J A Punt; J T M Plukker; H M W Verheul; E J Spillenaar Bilgen; H van Dekken; M J C van der Sangen; T Rozema; K Biermann; J C Beukema; A H M Piet; C M van Rij; J G Reinders; H W Tilanus; A van der Gaast Journal: N Engl J Med Date: 2012-05-31 Impact factor: 91.245
Authors: Brendon M Stiles; Farooq Mirza; Anthony Coppolino; Jeffrey L Port; Paul C Lee; Subroto Paul; Nasser K Altorki Journal: Ann Thorac Surg Date: 2011-06-24 Impact factor: 4.330
Authors: Katrin M Sjoquist; Bryan H Burmeister; B Mark Smithers; John R Zalcberg; R John Simes; Andrew Barbour; Val Gebski Journal: Lancet Oncol Date: 2011-06-16 Impact factor: 41.316
Authors: Shaun McKenzie; Brian Mailey; Avo Artinyan; Michelle Metchikian; Stephen Shibata; Kemp Kernstine; Joseph Kim Journal: Ann Surg Oncol Date: 2010-09-14 Impact factor: 5.344
Authors: Patrick E Young; Andrew B Gentry; Ruben D Acosta; Bruce D Greenwald; Mark Riddle Journal: Clin Gastroenterol Hepatol Date: 2010-09-08 Impact factor: 11.382
Authors: G Spizzo; D Öfner; A de Vries; P Lukas; G Steger; U Pluschnig; J Zacherl; J Widder; A Zabernigg; G Gastl; G Mühlmann Journal: Ann Surg Oncol Date: 2010-11-10 Impact factor: 5.344
Authors: Paul C Lee; Farooq M Mirza; Jeffrey L Port; Brendon M Stiles; Subroto Paul; Paul Christos; Nasser K Altorki Journal: J Thorac Cardiovasc Surg Date: 2011-03-12 Impact factor: 5.209
Authors: James Welsh; Stephen H Settle; Arya Amini; Lianchun Xiao; Akihiro Suzuki; Yuki Hayashi; Wayne Hofstetter; Ritsuko Komaki; Zhongxing Liao; Jaffer A Ajani Journal: Cancer Date: 2011-10-05 Impact factor: 6.860
Authors: Surya Say Biere; Kirsten W Maas; Luigi Bonavina; Josep Roig Garcia; Mark I van Berge Henegouwen; Camiel Rosman; Meindert N Sosef; Elly S M de Lange; H Jaap Bonjer; Miguel A Cuesta; Donald L van der Peet Journal: BMC Surg Date: 2011-01-12 Impact factor: 2.102
Authors: Inderpal S Sarkaria; Nabil P Rizk; Debra A Goldman; Camelia Sima; Kay See Tan; Manjit S Bains; Prasad S Adusumilli; Daniela Molena; Matthew Bott; Thomas Atkinson; David R Jones; Valerie W Rusch Journal: Ann Thorac Surg Date: 2019-04-23 Impact factor: 4.330
Authors: Tara R Semenkovich; Yan Yan; Melanie Subramanian; Bryan F Meyers; Benjamin D Kozower; Ruben Nava; G Alexander Patterson; Daniel Kreisel; Varun Puri Journal: Ann Surg Date: 2021-06-01 Impact factor: 13.787